292 related articles for article (PubMed ID: 33352195)
1. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
3. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
4. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
[TBL] [Abstract][Full Text] [Related]
7. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
8. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
Henske EP; Cornejo KM; Wu CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
[TBL] [Abstract][Full Text] [Related]
10. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic solid and cystic renal cell carcinoma: A rare under-recognized indolent entity.
Kamboj M; Gupta G; Pasricha S; Rawal S; Sharma A; Durga G; Mehta A
Indian J Pathol Microbiol; 2021; 64(4):799-801. PubMed ID: 34673608
[TBL] [Abstract][Full Text] [Related]
14. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
15. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
[TBL] [Abstract][Full Text] [Related]
16. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
[TBL] [Abstract][Full Text] [Related]
17. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
Hartmann A; Agaimy A
Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
[TBL] [Abstract][Full Text] [Related]
18. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.
Shah RB; Mehra R
Adv Anat Pathol; 2024 Mar; 31(2):105-117. PubMed ID: 37899532
[TBL] [Abstract][Full Text] [Related]
19. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
20. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
